Shionogi Pharmaceutical
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Shionogi Pharmaceutical - overview
Established
1992
Location
-, Osaka, Japan
Primary Industry
Pharmaceuticals
About
Shionogi Pharmaceutical is a Japan-based company specializing in the development of innovative pharmaceuticals focused on infectious diseases, pain management, and central nervous system disorders, delivering a variety of therapeutic solutions globally. Shionogi & Co. , Ltd. , founded in 1992 in Japan, engages in the research and development of pharmaceutical products.
The company operates globally, with headquarters located in Osaka. The founders, Braden Pierce and Umesh Bordivekar, established the firm to address critical health challenges. In April 2022, Shionogi Pharmaceutical raised funds through a financial transaction, which remains undisclosed. The company has completed 1 deal to date.
Shionogi specializes in developing and providing pharmaceutical products across various therapeutic areas including infectious diseases, pain management, and central nervous system disorders. Their offerings encompass both prescription medications and over-the-counter (OTC) products, aimed at improving the quality of life for patients. Notable products feature antibacterial agents and chronic pain treatments, catering to a diverse client base that includes healthcare providers and patients across Japan, North America, and Europe. In the year 2023, Shionogi reported a revenue of USD 3.
16 bn, alongside an EBITDA of USD 1. 23 bn. The company primarily generates revenue through direct sales of its pharmaceutical products to healthcare institutions and retailers, emphasizing B2B transactions with hospitals and pharmacies to facilitate medication distribution. Shionogi's revenue streams are driven by the demand for its recognized products in the healthcare market.
Shionogi Pharmaceutical plans to utilize funding raised in April 2022 to conduct clinical research on innovative antibacterial drugs aimed at combating multidrug-resistant bacteria. The company is focused on launching new products designed to enhance its therapeutic portfolio. Additionally, Shionogi is exploring expansion into emerging markets in Asia and beyond, with targeted initiatives expected to unfold over the next few years.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals, Logistics & Distribution
Website
www.shionogi.co.jp
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Shionogi Pharmaceutical - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | C&O Pharmaceutical Technology | - | ||||||||
| Buyout | Completed | Bushu Pharmaceuticals Co., Ltd. | - | ||||||||
| Buyout | Completed | Qualicaps Group | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.